30 November 2021 in Dermatology and Therapy
Introduction Individuals with alopecia areata (AA) may experience significant impacts on their health-related quality of life. The novel Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire has been developed to assess hair loss signs, emotional symptoms, and activity limitations associated with AA. The objective of this study was to evaluate psychometric properties and establish scoring of the AAPPO in adults and adolescents with AA. Methods Scoring and measurement properties of the AAPPO were examined using baseline and 2-week follow-up data from a prospective, noninterventional, web-based study of 121 patients with AA (85 adults aged ≥ 18 years, 36 adolescents aged 12–17 years) with Severity of Alopecia Tool (SALT) ≥ 25% scalp hair loss. Results Exploratory and confirmatory factor analysis supported four single Hair Loss (HL) items, an Emotional Symptoms domain (ES; 4 items), and an Activity Limitations domain (AL; 3 items). Among all patients, the multi-item ES and AL domains had strong internal consistency (α ≥ 0.87); all HL items and domain scores had strong test-retest reliability (weighted kappa or intraclass correlation coefficients ≥ 0.78). All HL item scores demonstrated strong construct validity (r ≥ 0.52) compared with the patient-reported Alopecia Areata Symptom and Impact Scale (AASIS) hair loss subscale score; ES and AL domain scores exhibited strong construct validity (r ≥ 0.66) compared with the SF-36 Mental Component Summary (MCS) score. Using SALT scores, HL mean item scores were better (lower) in the 25–49% SALT subgroup versus those with highest SALT scores (76–100%); however, ES mean domain scores were better in the SALT 76–100% subgroup in the same comparison (p < 0.0001). Using AASIS and MCS score–created subgroups, ES and AL mean domain scores demonstrated hypothesized differences across subgroups (all p values < 0.0001). Conclusion The AAPPO questionnaire is a reliable, valid disease-specific measure of hair loss severity and impact in individuals with AA.
1 March 2012 in Journal of Studies on Alcohol and Drugs
Objective:This study evaluated the costs and cost-effectiveness of combining motivational interviewing with feedback to address heavy drinking among university freshmen.Method:Microcosting methods ...
13 November 2022 in Quality of Life Research
1 May 2015 in Value in Health
5 August 2025 in British Journal of Dermatology
Background: Hidradenitis suppurativa (HS) is associated with a substantial disease burden. Given the complex nature of HS-related symptoms, patient-reported outcome (PRO) measures are important to ensure that the patient experience is captured when evaluating the efficacy of treatments in clinical trials. Objectives: To develop the Hidradenitis Suppurativa Symptom and Impact Diary (HSSID©), a novel PRO measure for use in clinical trials to assess the symptoms and impacts of HS in adult patients, and to validate its psychometric properties. Methods: The development phase involved patients with HS and clinicians with HS expertise and included three sequential stages: (i) concept elicitation interviews (n = 8); (ii) item development; and (iii) cognitive debriefing interviews (n = 12). The psychometric properties of the HSSID were evaluated using data from a subset of patients participating in the SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) trials, and included assessments of reliability, validity and ability to detect change. Anchor-based methods to estimate meaningful change thresholds were explored. Results: The HSSID comprises 11 items; 5 relate to HS symptoms (lesion-related pain, lesion-related itching, lesion drainage, odour and physical fatigue) and 6 to HS impacts (ability to walk, ability to move [other than walking], sleep disturbance, time spent with other people, negative impact on emotions and ability to complete work). Patients found the HSSID items easy to understand and reported no difficulties recalling symptoms/impacts experienced in the previous 24 h. Overall, 478 patients from SUNSHINE and SUNRISE were included in the psychometric evaluation phase. Good association with low redundancy was observed among HSSID items with moderate (> 0.30) to strong (> 0.50) inter-diary item correlations among symptoms and impact items, and across groups. Test–retest reliability estimates in stable subsets were high across SUNSHINE and SUNRISE, ranging from 0.78 to 0.96. Construct validity analysis confirmed that each HSSID item correlated with ≥ 1 targeted support variable. HSSID item scores demonstrated satisfactory responsiveness to detect change; however, anchor-based meaningful change thresholds could be established for the worst lesion-related pain item only. Conclusions: The HSSID appropriately assesses the symptoms and impacts of HS in adults. HSSID items demonstrated generally robust psychometric properties.
10 April 2022 in Dermatology and Therapy